Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.16-1.61 (-2.02%)
As of 3:07 PM EDT. Market open.
People also watch:
CELGBIIBAMGNREGNFB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open79.65
Prev Close79.77
Bid78.13 x 100
Ask78.14 x 700
Day's Range77.63 - 79.70
52wk Range77.63 - 113.31
1y Target EstN/A
Market Cap103.14B
P/E Ratio (ttm)6.86
Beta0.99
Volume12,717,012
Avg Vol (3m)10,159,655
Dividend & Yield1.88 (2.36%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com51 minutes ago

    Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors

    Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.

  • Barrons.com2 hours ago

    Gilead Sciences: Don't Expect Perfection

    As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.

  • Five Healthcare Stocks Hedge Funds Like
    Insider Monkey2 hours ago

    Five Healthcare Stocks Hedge Funds Like

    Times are tough for healthcare stocks as investors keep a distance from the sector following drug-pricing control concerns and political clamor. However, analysts think that as the overpricing factor trims, healthcare stocks become feasible to accumulate as long positions. For this article, we have used data from the latest round of 13F filings and have […]